A virus used in a Seattle company's gene therapy experiment likely didn't cause the death of a woman who had rheumatoid arthritis, although it can't be completely ruled out, government health advisers say.Advisers to the National Institutes of Health said that a massive fungal infection is near the top of the list of likely culprits in the death of Jolee Mohr.Mohr, 36, died at University of Chicago Medical Center on July 24, several weeks after receiving the second injection of trillions of genetically altered viruses at the Arthritis Center in Springfield, Ill., as part of a gene therapy study for rheumatoid arthritis.Doctors have since struggled to determine how she died, though a massive Histoplasma capsulatum infection appears to be a leading cause. Advisers to the National Institutes of Health met Monday to hear autopsy results and other evidence to determine what role - if any - the injected virus also may have played.The genetically engineered virus was used as a vector or vehicle to carry a new gene into Mohr's body, helping it to make a protein that would ease her arthritis pain.

Enter details below to receive more information. Your Privacy is 100% safe!

Can-Fite BioPharma has developed a test to improve the odds of successful clinical trials on the company's pharmaceuticals.

The medical technology company develops drugs related to A3 adenosine receptors. The point being - this receptor is found in large quantities in inflamed and cancerous cells, but less so in healthy cells. The company's blood test measures the level of A3 adenosine, which reflects the number of diseased cells.

Enter details below to receive more information. Your Privacy is 100% safe!